SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sofia Sapeta Dias, David A. Isenberg, Advances in systemic lupus erythematosus, Medicine, 2014, 42, 3, 126

    CrossRef

  2. 2
    Vijay Rao, Caroline Gordon, Advances in the assessment of lupus disease activity and damage, Current Opinion in Rheumatology, 2014, 26, 5, 510

    CrossRef

  3. 3
    Y. Wang, F. Yu, D. Song, S.-X. Wang, M.-H. Zhao, Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre, Rheumatology, 2014, 53, 7, 1235

    CrossRef

  4. 4
    Veronica Rodriguez-Garcia, Sofia Sapeta Dias, David Isenberg, Recent advances in the treatment of systemic lupus erythematosus, International Journal of Clinical Rheumatology, 2014, 9, 1, 89

    CrossRef

  5. 5
    Bevra H. Hahn, Jennifer K. King, The Autoimmune Diseases, 2014,

    CrossRef

  6. 6
    See Yeo, Khoon Chuah, Hwei Lee, Adrian Liew, An unusual case of glomerulonephritis in a patient with non-Hodgkin Mucosal Associated Lymphoid Tissue (MALT) B-cell lymphoma, BMC Nephrology, 2013, 14, 1, 158

    CrossRef

  7. 7
    Anna Nuttall, David A. Isenberg, Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: New aspects, Best Practice & Research Clinical Rheumatology, 2013, 27, 3, 309

    CrossRef

  8. 8
    Azrin N. Abd Rahman, Susan E. Tett, Christine E. Staatz, Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Patients with Autoimmune Disease, Clinical Pharmacokinetics, 2013, 52, 5, 303

    CrossRef

  9. 9
    José M. Pego-Reigosa, Tatiana Cobo-Ibáñez, Jaime Calvo-Alén, Estíbaliz Loza-Santamaría, Anisur Rahman, Santiago Muñoz-Fernández, Íñigo Rúa-Figueroa, Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review, Arthritis Care & Research, 2013, 65, 11
  10. 10
    I. Kötter, J.C. Henes, Etablierte Medikamente, Zeitschrift für Rheumatologie, 2013, 72, 9, 853

    CrossRef

  11. 11
    Manuel F Ugarte-Gil, Graciela S Alarcón, Is there an effective treatment for late-onset systemic lupus erythematosus?, Aging Health, 2013, 9, 4, 437

    CrossRef

  12. 12
    C. Fiehn, G. Keyßer, H.-M. Lorenz, Personalisierte Medizin in der Auswahl konventioneller Immunsuppressiva und „disease modifying anti-rheumatic drugs“, Zeitschrift für Rheumatologie, 2013, 72, 1, 27

    CrossRef

  13. 13
    M. Aringer, R. Fischer-Betz, F. Hiepe, Stellungnahme zum Einsatz von Mycophenolat-Mofetil beim systemischen Lupus erythematodes, Zeitschrift für Rheumatologie, 2013, 72, 6, 575

    CrossRef

  14. 14
    Remco K.M.A.C. Luijten, Ruth D. Fritsch-Stork, Johannes W.J. Bijlsma, Ronald H.W.M. Derksen, The use of glucocorticoids in Systemic Lupus Erythematosus. After 60years still more an art than science, Autoimmunity Reviews, 2013, 12, 5, 617

    CrossRef

  15. 15
    Jonathan Hogan, Gerald B. Appel, Update on the treatment of lupus nephritis, Current Opinion in Nephrology and Hypertension, 2013, 22, 2, 224

    CrossRef

  16. 16
    George Bertsias, Antonios Fanouriakis, Dimitrios T. Boumpas, Kelley's Textbook of Rheumatology, 2013,

    CrossRef

  17. 17
    W. Joseph McCune, Tania Gonzalez-Rivera, Dubois' Lupus Erythematosus and Related Syndromes, 2013,

    CrossRef

  18. 18
    A. Devlin, R. Ramsey-Goldman, K.H. Costenbader, Women and Health, 2013,

    CrossRef

  19. 19
    Mathieu Artifoni, Xavier Puéchal, Lupus érythémateux, 2013,

    CrossRef

  20. 20
    Sandra V. Navarra, Tito P. Torralba, Dubois' Lupus Erythematosus and Related Syndromes, 2013,

    CrossRef

  21. 21
    N. Ranawaka, I. Atukorala, N. Fernandopulle, M. Nawarathna, An unusual cause of generalized oedema in systemic lupus erythematosus, Rheumatology, 2012, 51, 12, 2298

    CrossRef

  22. 22
    Mathieu Artifoni, Xavier Puéchal, Comment traiter une arthrite réfractaire au cours du lupus ?, Revue du Rhumatisme, 2012, 79, 5, 393

    CrossRef

  23. 23
    Manuel Ramos-Casals, Munther A. Khamashta, Connective tissue disease: Trial of SLE therapies in real-world settings, Nature Reviews Rheumatology, 2012, 8, 3, 128

    CrossRef

  24. 24
    Mathieu Artifoni, Xavier Puéchal, How to treat refractory arthritis in lupus?, Joint Bone Spine, 2012, 79, 4, 347

    CrossRef

  25. You have free access to this content25
    Joan T. Merrill, Ellen M. Ginzler, Daniel J. Wallace, James D. McKay, Jeffrey R. Lisse, Cynthia Aranow, Frank R. Wellborne, Michael Burnette, John Condemi, Z. John Zhong, Lilia Pineda, Jerry Klein, William W. Freimuth, Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus, Arthritis & Rheumatism, 2012, 64, 10
  26. 26
    Kjell Tullus, New developments in the treatment of systemic lupus erythematosus, Pediatric Nephrology, 2012, 27, 5, 727

    CrossRef

  27. 27
    Jonathan Hogan, Michael H Schwenk, Jai Radhakrishnan, Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?, Kidney International, 2012, 82, 12, 1256

    CrossRef

  28. 28
    Grant W. Cannon, Goldman's Cecil Medicine, 2012,

    CrossRef

  29. 29
    Antonis Fanouriakis, Dimitrios T Boumpas, George K Bertsias, Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus, Expert Review of Clinical Pharmacology, 2011, 4, 4, 437

    CrossRef

  30. 30
    Vibeke Strand, Alvina D Chu, Measuring outcomes in systemic lupus erythematosus clinical trials, Expert Review of Pharmacoeconomics & Outcomes Research, 2011, 11, 4, 455

    CrossRef

  31. 31
    Maria Dall’Era, Mycophenolate mofetil in the treatment of systemic lupus erythematosus, Current Opinion in Rheumatology, 2011, 23, 5, 454

    CrossRef

  32. 32
    Mary Anne Dooley, David Jayne, Ellen M. Ginzler, David Isenberg, Nancy J. Olsen, David Wofsy, Frank Eitner, Gerald B. Appel, Gabriel Contreras, Laura Lisk, Neil Solomons, Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis, New England Journal of Medicine, 2011, 365, 20, 1886

    CrossRef

  33. 33
    A. Schwarting, Nierenbeteiligung beim systemischen Lupus erythematodes, Der Nephrologe, 2011, 6, 3, 258

    CrossRef

  34. 34
    Vladimir Tesar, Zdenka Hruskova, Treatment of proliferative lupus nephritis: a slowly changing landscape, Nature Reviews Nephrology, 2011, 7, 2, 96

    CrossRef

  35. 35
    Diane Horowitz, Galina Marder, Richard Furie, Systemic Lupus Erythematosus, 2011,

    CrossRef

  36. 36
    Joan T. Merrill, Kenneth C. Kalunian, Jill P. Buyon, Systemic Lupus Erythematosus, 2011,

    CrossRef

  37. 37
    Eva D. Papadimitraki, George Bertsias, George Chamilos, Dimitrios T. Boumpas, Systemic Lupus Erythematosus, 2011,

    CrossRef

  38. 38
    Ana M Bertoli, Graciela S Alarcón, Perspectives on the management of late-onset systemic lupus erythematosus, Aging Health, 2010, 6, 4, 475

    CrossRef

  39. 39
    Meenakshi Jolly, Pitfalls and Opportunities in Measuring Patient Outcomes in Lupus, Current Rheumatology Reports, 2010, 12, 4, 229

    CrossRef

  40. 40
    J. Pope, The revised BILAG Index with numerical scoring in systemic lupus erythematosus: added value with some limitations, Rheumatology, 2010, 49, 9, 1616

    CrossRef

  41. 41
    Susan Jessop, David Whitelaw, Cutaneous Lupus Erythematosus,
  42. 42
    Lorna Henderson, Philip Masson, Jonathan C Craig, Robert S Flanc, Matthew A Roberts, Giovanni FM Strippoli, Angela C Webster, Treatment for lupus nephritis, The Cochrane Library,